Mr Mathias Azevedo Bastian Bressel
Honorary Senior Fellow
The Sir Peter MacCallum Department of Oncology
297 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma
DOI: 10.1038/s41467-026-74255-x2026
Journal article
Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial
DOI: 10.1038/s41467-026-75660-y2026
Journal article
Tumor-Intrinsic Blood and Imaging Correlatives in Advanced Prostate Cancer Treated with Combination Radiopharmaceutical Therapy and Immunotherapy.
DOI: 10.2967/jnumed.126.2732662026
Journal article
Does stereotactic ablative body radiotherapy (SABR) added to continued systemic therapy improve time to treatment failure compared with physician's choice of systemic therapy in oligoprogressive ER-positive, HER2-negative advanced breast cancer? Study protocol for a multicentre, randomised, open-label phase II trial in Australian tertiary cancer centres (AVATAR-II)
DOI: 10.1136/bmjopen-2026-1198112026
Journal article
Patient Reported Symptom Trajectories during and after Radiotherapy (RT) for Human Papillomavirus-Associated Oropharyngeal Cancer (HPVOPC): A TROG 12.01 Secondary Analysis
DOI: 10.1016/j.ijrobp.2026.06.5542026
Research grants (other domestic)
Using PET Imaging to Predict Who Benefits From Early Upfront Lutetium-Psma Therapy in Men With Newly Diagnosed Advanced Prostate Cancer
2018
Journal article
Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma
DOI: 10.1056/NEJMoa1715519
RECENT SCHOLARLY WORKS
2026
Journal article
Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials
DOI: 10.1016/S1470-2045(26)00170-12026
Journal article
FAPI-CUP: A prospective cohort study of patients with cancer of unknown primary (CUP) to evaluate a novel radiotracer, fibroblast activated protein (FAPI), targeting cancer-associated fibroblasts for primary site detection.
DOI: 10.1200/jco.2026.44.16_suppl.30722026
Conference Proceedings
IGNITE-Cerala: A phase II signal-seeking trial of ceralasertib targeting recurrent high-grade serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.
DOI: 10.1200/jco.2026.44.16_suppl.55872026
Journal article
Evaluation of Clinical Outcomes and Pattern of Recurrence in Patients with Cutaneous Melanoma and Sentinel Lymph Node Positivity Since the Publication of the MSLT-2 Trial
DOI: 10.1245/s10434-026-19260-62026
Journal article
Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study
DOI: 10.1016/S1470-2045(26)00091-4